SEC Form 4 · accession 0001209191-19-012942
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carman Alenson
Officer — Principal Accounting Officer
Period of report
Feb 21, 2019
Accepted (ET)
Feb 25, 2019 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | Feb 21, 2019 | M | 3,300 | — | A | 3,812 | D | |
| Common stock | Feb 21, 2019 | F | 1,016 | $56.33 | D | 2,796 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted stock unitsF1,F2 | — | Feb 21, 2019 | M | 3,300 | D | — | — | Common stock | 3,300 | 0 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F2All of the restricted stock units vested on February 21, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.